LOXL2 and neoplasm: However, a recent study, by H. Jiang et al., reported that, in multiple immunocompetent experimental PDAC mouse models, anti-LOXL-2 treatment reduced fibrosis, decreased tissue tension reduction which, in turn, enhanced tumor progression (even in combination with gemcitabine) [349].